Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial
A phase 2 trial of Sapanisertib, Serabelisib, Paclitaxel / nab-paclitaxel in endometrial cancer, run by Faeth Therapeutics, now recruiting.
Overview
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer is a phase 2 interventional study registered as NCT06463028 by Faeth Therapeutics, with 40 participants planned, started 2024-12-12 and due to reach its primary completion in 2028-09. Interventions recorded: Sapanisertib, Serabelisib, Paclitaxel. Conditions listed: Endometrial Cancer. No results are recorded here; the registry entry is the source.
Setting
An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer
Phase
Phase 2
Sponsor
Faeth Therapeutics
Registry
Enrolled
40
Similar pages
not linked directly; found by shared links- TrialSapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Shares Sapanisertib, Serabelisib.
- TrialA Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
- TrialSacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
- TrialA Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
- TrialStudy of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Im
- TrialPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- TrialA Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- TrialStudy of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer